Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science
29 November 2016 - 12:00AM
Business Wire
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical
company developing CODIT™ (Characterized Oral
Desensitization ImmunoTherapy) treatments for
life-threatening food allergies, today announced the closing of the
$145 million equity investment by Nestlé Health Science. Nestlé
Health Science purchased 7,552,084 shares of Aimmune's common stock
at $19.20 per share on November 23, 2016, in a private placement
transaction. The sale of shares was made pursuant to the terms of
the Securities Purchase Agreement entered into on November 3, 2016,
by Aimmune and Nestlé Health Science, as previously reported by
Aimmune. In connection with the closing of the equity investment,
Greg Behar, Chief Executive Officer of Nestlé Health Science, was
appointed to Aimmune’s board of directors on November 23, 2016.
Aimmune has a total of 50,044,727 shares of common stock
outstanding after taking into account the shares issued to Nestlé
Health Science.
Additional details regarding the equity investment and strategic
collaboration agreement can be found in Aimmune's Form 8-K filed
with the Securities and Exchange Commission on November 4,
2016.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage
biopharmaceutical company developing treatments for
life-threatening food allergies. The company’s Characterized
Oral Desensitization ImmunoTherapy
(CODIT™) approach is intended to achieve meaningful levels of
protection by desensitizing patients with defined, precise amounts
of key allergens. Aimmune’s first investigational product using
CODIT™, AR101 for the treatment of peanut allergy, has received the
FDA’s Breakthrough Therapy Designation for the desensitization of
peanut-allergic patients 4-17 years of age and is currently being
evaluated in Phase 3 clinical trials in ages 4-55. AR101 is a
characterized, regulated, oral biological drug product containing
the protein profile found in peanuts. For more information, please
see www.aimmune.com.
This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by
the U.S. Food and Drug Administration (FDA) or the European
Medicines Agency (EMA). It is currently limited to investigational
use, and no representation is made as to its safety or
effectiveness for the purposes for which it is being
investigated.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161128005138/en/
Aimmune Therapeutics, Inc.InvestorsLaura Hansen, Ph.D.,
650-396-3814lhansen@aimmune.comorMediaStephanie Yao,
650-351-6479syao@aimmune.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Apr 2024 to May 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From May 2023 to May 2024